MedEffect e-Notice from Health Canada | Safety Warning Regarding Arthritis Drug

On May 21, 2019 Health Canada released a MedEffect Notice advising of a risk of serious drug-induced liver injury, at times resulting in acute liver failure and requiring a transplant for patients using ACTEMRA. It is an intravenous and subcutaneous drug prescribed for treatment of Rheumatoid Arthritis, Giant Cell Arteritis, Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis. Medical practitioners are being advised to discontinue use in patients with hepatic impairment and to test liver enzymes before and during treatment.